MedImmune and Advaxis partner on immuno-oncology combination clinical trial
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
- Details
- Category: AstraZeneca
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre(1).
Novartis maintained strong innovation momentum in second quarter
- Details
- Category: Novartis
Novartis Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter. Group operating income increased 6% (+11% cc) to USD 3.1 billion. Currency had a negative impact of 5 percentage points, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.
Pfizer to Acquire InnoPharma, Inc.
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.
Novartis to license Google "smart lens" technology
- Details
- Category: Novartis
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems,
Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
CliniWorks forms a strategic alliance with Pfizer
- Details
- Category: Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. ("CliniWorks Israel") and Pfizer Inc. ("Pfizer") to jointly advance the parties' respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health.
More Pharma News ...
- Merck Serono announces Global Grants Program to fund scientific innovation
- AstraZeneca and Max Planck Institute announce research agreement
- Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials (IITs)
- Roche announces definitive agreement to acquire Seragon Pharmaceuticals
- Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia
- Boehringer Ingelheim Statement on Hepatitis C drug development
- James C. Smith elected to Pfizer's Board of Directors